[Translation] A single-center, open-label, dose-escalating Phase Ia clinical study to investigate the safety, tolerability, and pharmacokinetics of metoprolol (HcHAb18) monoclonal antibody injection
本研究是单中心、开放、剂量递增的Ia期临床研究,目的是考察剂量递增的美妥珠(HcHAb18)单抗注射液在标准治疗失败的非小细胞肺癌患者中的安全性、耐受性以及药代动力学特征,确定最大耐受剂量,同时初步考察美妥珠单抗的抗肿瘤活性,为后续临床研究的用药方案提供依据。
[Translation] This study is a single-center, open-label, dose-escalating Phase Ia clinical study. Its purpose is to investigate the safety, tolerability, and pharmacokinetic characteristics of escalating doses of metuzoumab (HcHAb18) monoclonal antibody injection in patients with non-small cell lung cancer who have failed standard treatment, determine the maximum tolerated dose, and preliminarily investigate the anti-tumor activity of metuzoumab to provide a basis for the medication regimen of subsequent clinical studies.